Compounds and inhibitors of phospholipases

Details Compounds and inhibitors of phospholipases Compounds and inhibitors of phospholipases

2007-08-07

2007-08-07

Solola, Taofiq (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S459000, C514S617000, C546S339000, C549S427000, C564S161000

Reexamination Certificate

active

10333871

ABSTRACT:
The present invention relates generally to amino acid derivatives and to methods of making the same. In particular, the invention relates to compounds bearing a stereochemical identity, that is, the same stereochemistry, with the chiral α-carbon of D-α-amino acids and their use in methods of therapy, including the treatment of inflammatory diseases, and to compositions and enantiomeric mixtures containing them.

REFERENCES:
patent: 5455271 (1995-10-01), Yuan et al.
patent: 5481011 (1996-01-01), Chen et al.
patent: 5916878 (1999-06-01), Kolobov et al.
patent: 2002/0128255 (2002-09-01), Beck et al.
patent: 2004/0247639 (2004-12-01), Shiels et al.
patent: 691345 (1996-01-01), None
patent: 91/08737 (1991-06-01), None
patent: 9400420 (1994-01-01), None
patent: 94/28004 (1994-12-01), None
patent: 95/19959 (1995-07-01), None
patent: 97/03951 (1997-02-01), None
patent: 9838167 (1998-09-01), None
patent: 2002002512 (2002-01-01), None
Teno et al., Chem. Pharm. Bull. (1993), vol. 41(6), pp. 1079-1080.
Bae, J. et al., “Stimulation of pregnant rat uterine contraction by the polychlorinated biphenyl (PCB) mixture aroclor 1242 may be mediated by arachidonic acid release through activation of phospholipase A2enzymes,” J. Pharmacol. and Exper. Therap. 289(2):1112-1120, 1999.
Balboa, M. A. et al., “Novel group V phospholipase A2involved in arachidonic acid mobilization in murine P388D, macrophages,” J. Biol. Chem. 271(50):32381-32384, 1996.
Benedetto, C., “Eicosanoids in primary dysmenorrheal, endometriosis and menstrual migraine,” Gynecol. Endocrinol. 3:71-94, 1989.
Bernal, A. L. et al., “Are leukotrienes involved in human uterine contractility?” Br. J. Obstet. Gynaecol. 96:568-573, 1989.
Bieglmayer, C. et al., “Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives,” Gynecol. Endocrinol. 9:307-312, 1995.
Hanasaki, K. et al., “Purified group X secretory phospholipase A2induced prominent release of arachidonic acid from human myeloid leukemia cells,” J. Biol. Chem. 274(48):34203-34211, Nov. 26, 1999.
Nattero, G. et al., “Relevance of prostaglandins in true menstrual migraine,” Headache 29:233-238, 1989.
Nigam, S. et al., “Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrheal,” Eicosanoids 4:137-141, 1991.
Pisabarro, M. T. et al., “Rational modification of human synovial fluid phospholipase A2inhibitors,” J. Med. Chem. 37:337-341, 1994.
Prigent, A. et al., “Prostaglandin E2production by uterine stromal cell line UIII: Regulation by estradiol and evidence of an ethanol action,” Prostaglandins 47:451-466, 1994.
Rice, G. E., “Secretory type II phospholipase A2and the generation of intrauterine signals,” Reprod. Fertil. Dev. 7:1471-1479, 1995.
Schevitz, R. W. et al., “Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2,” Nat. Struct. Biol. 2(6):458-465, 1995.
Thunnissen, M. M. G. M. et al., “X-ray structure of phospholipase A2complexed with a substrate-derived inhibitor,” Nature 347:689-691, 1990.
Zahradnik, H. P. et al., “Contribution to the pathogenesis of dysmenorrheal,” Arch. Gynecol. 236:99-108, 1984.
J. Balsinde et al.,Regulation and Inhibition of PhospholipaseA2, Annual Review of Pharmacology and Toxicology 39:175-190, Apr. 1999.
H. Beaton et al.,Discovery of New Non-Phospholipid Inhibitors of the Secretory PhospholipasesA2, Chemical Abstract 120:238899, 1994.
H. Beaton et al.,Discovery of New Non-Phospholipid Inhibitors of the Secretory PhospholipasesA2, J. Med. Chem. 37(5):557-559, 1994.
S.-S. Cha et al.,High-Resolution X-Ray Crystallography Reveals Precise Binding Interactions Between Human Nonpancreatic Secreted PhospholipaseA2and a Highly Potent Inhibitor, Chemical Abstract 125:241668, 1996.
S.-S. Cha et al.,High-Resolution X-Ray Crystallography Reveals Precise Binding Interactions Between Human Nonpancreatic Secreted Phospholipase A2and a Highly Potent Inhibitor(FPL67047XX), J. Med. Chem. 39(20):3878-3881, 1996.
E. Dennis,The Growing Phospholipase A2Superfamily of Signal Transduction Enzymes, TIBS 22:1-2, Jan. 1997.
A. Deveer et al.,Competitive Inhibition of Lipolytic Enzymes. VII. The Interaction of Pancreatic PhospholipaseA2With Micellar Lipid/Water Interfaces of Competitive Inhibotors, Chemical Abstract 117:65348, 1992.
A. Deveer et al.,Competitive Inhibition of Lipolytic Enzymes. VII. The Interaction of Pancreatic PhospholipaseA2with Micellar Lipid/Water Interfaces of Competitive Inhibitors, Biochimica Biophysica Acta 1125(1):73-81, 1992.
M. Garcia et al.,A Convenient Synthesis of 1-ether-2-acylamido-2-deoxy-sn-glycerophospholipids, Chemical Abstract 120:245643, 1993.
M. Garcia et al.,A Convenient Synthesis of 1-ether-2-acylamido-2-deoxy-sn-glycerophospholipids, Synthetic Communications 23(22):3165-3177, 1993.
H. Meyer et al.,Comparative Studies of Tyrosine Modification in Pancreatic Phospholipases. 2. Properties of the Nitrotyrosyl, Aminotyrosyl, and Dansylaminotyrosyl Derivatives of Pig, Horse, and Ox PhospholipasesA2and Their Zymogens, Chemical Abstract 91:104450, 1979.
H. Meyer et al.,Comparative Studies of Tyrosine Modification in Pancreatic Phospholipases. 2. Properties of the Nitrotyrosyl, Aminotyrosyl, and Dansylaminotyrosyl Derivatives of Pig, Horse, and Ox Phospholipases A2and Their Zymogens, Biochemistry 18(16):3589-3597, 1979.
M. Murakami et al.,Different Functional Aspects of the Group II Subfamily(Types IIA and V)and Type X Secretory Phospholipase A2s in Regulating Arachidonic Acid Release and Prostaglandin Generation, J. Biol. Chem. 274(44):31435-31444, Oct. 29, 1999.
A. Ortiz et al.,Reliability of CoMFA Models: Effects of Data Scaling and Variable Selection Using a Set of Human Synovial Fluid Phospholipase A2Inhibitors, Chemical Abstract 128:97306, 1997.
A. Ortiz et al.,Reliability of Comparative Molecular Field Analysis Models: Effects of Data Sealing and Variable Selection Using a Set of Human Synovial Fluid Phospholipase A2 INhibitors, J. Med. Chem. 40:1138-1148, 1997.
A. Ortiz et al.,Reliability of CoMFA Models: Effects of Data Scaling and Variable Selection Using a Set of Human Synovial Fluid Phospholipase A2Inhibitors, Additions and Corrections, J. Med. Chem. 40(25):4168, 1997.
W. Pruzanski et al.,Phospholipase A2—A Mediator Between Proximal and Distal Effectors of Inflammation, Immunology Today 12(5):143-146, 1991.
W. Yuan et al.,Synthesis of Sulfur-Substituted Phospholipid Analogs as Mechanistic Probes of Phospholipase A2 Catalysis, Chemical Abstract 110:95663, 1989.
W. Yuan et al.,Synthesis of Sulfur-Substituted Phospholipid Analogues as Mechanistic Probes of Phospholipase A2Catalysis, J. Org. Chem. 54(4):906-910, 1989.
R. C. Reid, “Inhibitors of secretory phospholipase A2 Group IIA,” Current Medicinal Chemistry 12:3011-3026, 2005.
H. Bundgaard, “Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entitles,” In: Design of Prodrugs, H. Bundgaard (ed.), Elsevier Science Publishers, 1985, pp. 1-91.
K. A. Hansford et al., “D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (lla) with antiinflammatory activity,” ChemBioChem 4:181-185, 2003.

Affiliated with

Also associated with

Rating

Compounds and inhibitors of phospholipases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds and inhibitors of phospholipases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and inhibitors of phospholipases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3894469